• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血小板增加卵巢癌中PD-L1的表达。

Platelets Increase the Expression of PD-L1 in Ovarian Cancer.

作者信息

Cho Min Soon, Lee Hani, Gonzalez-Delgado Ricardo, Li Dan, Sasano Tomoyuki, Carlos-Alcalde Wendolyn, Ma Qing, Liu Jinsong, Sood Anil K, Afshar-Kharghan Vahid

机构信息

Section of Benign Hematology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Department of Hematopoietic Biology and Malignancy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

出版信息

Cancers (Basel). 2022 May 19;14(10):2498. doi: 10.3390/cancers14102498.

DOI:10.3390/cancers14102498
PMID:35626102
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9139585/
Abstract

The interactions between platelets and cancer cells activate platelets and enhance tumor growth. Platelets increase proliferation and epithelial-mesenchymal transition in cancer cells, inhibit anoikis, enhance the extravasation of cancer cells, and protect circulating tumor cells against natural killer cells. Here, we have identified another mechanism by which platelets dampen the immune attack on cancer cells. We found that platelets can blunt the antitumor immune response by increasing the expression of inhibitory immune checkpoint (PD-L1) on ovarian cancer cells in vitro and in vivo. Platelets increased PD-L1 in cancer cells via contact-dependent (through NF-κB signaling) and contact-independent (through TFGβR1/Smad signaling) pathways. Inhibition of NF-κB or TGFβR1 signaling in ovarian cancer cells abrogated platelet-induced PD-L1 expression. Reducing platelet counts or inhibiting platelet functions reduced the expression of PD-L1 in ovarian cancer. On the other hand, an increase in platelet counts increased the expression of PD-L1 in tumor-bearing mice.

摘要

血小板与癌细胞之间的相互作用会激活血小板并促进肿瘤生长。血小板可增加癌细胞的增殖和上皮-间质转化,抑制失巢凋亡,增强癌细胞的外渗,并保护循环肿瘤细胞免受自然杀伤细胞的攻击。在此,我们发现了血小板抑制对癌细胞免疫攻击的另一种机制。我们发现,血小板可通过在体外和体内增加卵巢癌细胞上抑制性免疫检查点(PD-L1)的表达来减弱抗肿瘤免疫反应。血小板通过接触依赖性(通过NF-κB信号传导)和非接触依赖性(通过TFGβR1/Smad信号传导)途径增加癌细胞中的PD-L1。抑制卵巢癌细胞中的NF-κB或TGFβR1信号传导可消除血小板诱导的PD-L1表达。降低血小板计数或抑制血小板功能可降低卵巢癌中PD-L1的表达。另一方面,增加血小板计数可增加荷瘤小鼠中PD-L1的表达。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf02/9139585/255e852ecd50/cancers-14-02498-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf02/9139585/d68246a9e613/cancers-14-02498-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf02/9139585/b39fed0bb304/cancers-14-02498-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf02/9139585/b50a16e91bc5/cancers-14-02498-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf02/9139585/8abdca008992/cancers-14-02498-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf02/9139585/255e852ecd50/cancers-14-02498-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf02/9139585/d68246a9e613/cancers-14-02498-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf02/9139585/b39fed0bb304/cancers-14-02498-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf02/9139585/b50a16e91bc5/cancers-14-02498-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf02/9139585/8abdca008992/cancers-14-02498-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf02/9139585/255e852ecd50/cancers-14-02498-g005.jpg

相似文献

1
Platelets Increase the Expression of PD-L1 in Ovarian Cancer.血小板增加卵巢癌中PD-L1的表达。
Cancers (Basel). 2022 May 19;14(10):2498. doi: 10.3390/cancers14102498.
2
PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer.转移性乳腺癌患者循环肿瘤细胞和血小板上的 PD-L1 表达。
PLoS One. 2021 Nov 15;16(11):e0260124. doi: 10.1371/journal.pone.0260124. eCollection 2021.
3
Platelets stimulate programmed death-ligand 1 expression by cancer cells: Inhibition by anti-platelet drugs.血小板通过癌细胞刺激程序性死亡配体 1 的表达:抗血小板药物的抑制作用。
J Thromb Haemost. 2021 Nov;19(11):2862-2872. doi: 10.1111/jth.15478. Epub 2021 Aug 8.
4
Regulation of PD-L1 Expression by NF-κB in Cancer.NF-κB 对肿瘤中 PD-L1 表达的调控。
Front Immunol. 2020 Nov 25;11:584626. doi: 10.3389/fimmu.2020.584626. eCollection 2020.
5
Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.联合靶向 TNFR2 和 PD-1/PD-L1 信号通路的癌症免疫疗法可降低胰腺肿瘤微环境中的免疫抑制作用。
J Immunother Cancer. 2022 Mar;10(3). doi: 10.1136/jitc-2021-003982.
6
Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy.抗代谢物培美曲塞为免疫检查点阻断治疗营造有利的肿瘤微环境。
J Immunother Cancer. 2020 Nov;8(2). doi: 10.1136/jitc-2020-001392.
7
Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer.化疗通过核因子-κB 诱导程序性细胞死亡配体 1 过表达,促进卵巢癌中免疫抑制性肿瘤微环境。
Cancer Res. 2015 Dec 1;75(23):5034-45. doi: 10.1158/0008-5472.CAN-14-3098. Epub 2015 Nov 16.
8
Shikonin-mediated PD-L1 degradation suppresses immune evasion in pancreatic cancer by inhibiting NF-κB/STAT3 and NF-κB/CSN5 signaling pathways.紫草素通过抑制 NF-κB/STAT3 和 NF-κB/CSN5 信号通路降解 PD-L1,抑制胰腺癌的免疫逃逸。
Pancreatology. 2021 Apr;21(3):630-641. doi: 10.1016/j.pan.2021.01.023. Epub 2021 Feb 12.
9
Platelets promote invasion and induce epithelial to mesenchymal transition in ovarian cancer cells by TGF-β signaling pathway.血小板通过 TGF-β 信号通路促进卵巢癌细胞的侵袭并诱导上皮间质转化。
Gynecol Oncol. 2019 Jun;153(3):639-650. doi: 10.1016/j.ygyno.2019.02.026. Epub 2019 Mar 28.
10
Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.双重阻断 CXCL12-CXCR4 和 PD-1-PD-L1 通路可通过防止肿瘤微环境中的免疫抑制延长卵巢荷瘤小鼠的生存期。
FASEB J. 2019 May;33(5):6596-6608. doi: 10.1096/fj.201802067RR. Epub 2019 Feb 25.

引用本文的文献

1
B10 cell-induced PD-L1/PD-1-linked macrophage polarization in periodontitis.B10细胞诱导的牙周炎中与PD-L1/PD-1相关的巨噬细胞极化
J Transl Int Med. 2025 Jul 24;13(4):338-348. doi: 10.1515/jtim-2025-0038. eCollection 2025 Aug.
2
Platelets in Hepatocellular Carcinoma-From Pathogenesis to Targeted Therapy.肝细胞癌中的血小板——从发病机制到靶向治疗
Cancers (Basel). 2025 Jul 18;17(14):2391. doi: 10.3390/cancers17142391.
3
Innate Immunity and Platelets: Unveiling Their Role in Chronic Pancreatitis and Pancreatic Cancer.先天性免疫与血小板:揭示它们在慢性胰腺炎和胰腺癌中的作用

本文引用的文献

1
Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer.血小板 PD-L1 反映了肿瘤内 PD-L1 的集体表达,并预测了非小细胞肺癌的免疫治疗反应。
Nat Commun. 2021 Dec 1;12(1):7005. doi: 10.1038/s41467-021-27303-7.
2
PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer.转移性乳腺癌患者循环肿瘤细胞和血小板上的 PD-L1 表达。
PLoS One. 2021 Nov 15;16(11):e0260124. doi: 10.1371/journal.pone.0260124. eCollection 2021.
3
Platelets stimulate programmed death-ligand 1 expression by cancer cells: Inhibition by anti-platelet drugs.
Cancers (Basel). 2025 May 17;17(10):1689. doi: 10.3390/cancers17101689.
4
Genome-wide transcriptome analysis and drug target discovery reveal key genes and pathways in thyroid cancer metastasis.全基因组转录组分析与药物靶点发现揭示甲状腺癌转移中的关键基因和通路。
Front Endocrinol (Lausanne). 2025 Feb 10;16:1514264. doi: 10.3389/fendo.2025.1514264. eCollection 2025.
5
LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features.LORIS 使用常见的临床、病理和基因组特征,稳健地预测了接受免疫检查点阻断治疗的患者的预后。
Nat Cancer. 2024 Aug;5(8):1158-1175. doi: 10.1038/s43018-024-00772-7. Epub 2024 Jun 3.
6
Potential Role of Circulating PD-L1 Leukocytes as a Predictor of Response to Anti-PD-(L)1 Therapy in NSCLC Patients.循环PD-L1阳性白细胞作为非小细胞肺癌患者抗PD-(L)1治疗反应预测指标的潜在作用
Biomedicines. 2024 Apr 25;12(5):958. doi: 10.3390/biomedicines12050958.
7
Pre-treatment thrombocytosis and ovarian cancer survival: A meta-analysis.治疗前血小板增多症与卵巢癌生存率:一项荟萃分析。
Eur J Obstet Gynecol Reprod Biol X. 2024 May 4;22:100312. doi: 10.1016/j.eurox.2024.100312. eCollection 2024 Jun.
8
Ovarian cancer treatment and natural killer cell-based immunotherapy.卵巢癌治疗与自然杀伤细胞为基础的免疫疗法。
Front Immunol. 2023 Dec 21;14:1308143. doi: 10.3389/fimmu.2023.1308143. eCollection 2023.
9
Reprogramming the immunosuppressive tumor microenvironment: exploiting angiogenesis and thrombosis to enhance immunotherapy.重新编程免疫抑制性肿瘤微环境:利用血管生成和血栓形成增强免疫治疗。
Front Immunol. 2023 Jul 3;14:1200941. doi: 10.3389/fimmu.2023.1200941. eCollection 2023.
10
Development and validation of a novel anoikis-related gene signature for predicting prognosis in ovarian cancer.开发和验证一种新型的与细胞凋亡相关的基因标志物,用于预测卵巢癌的预后。
Aging (Albany NY). 2023 Apr 5;15(9):3410-3426. doi: 10.18632/aging.204634.
血小板通过癌细胞刺激程序性死亡配体 1 的表达:抗血小板药物的抑制作用。
J Thromb Haemost. 2021 Nov;19(11):2862-2872. doi: 10.1111/jth.15478. Epub 2021 Aug 8.
4
Aspirin and antiplatelet treatments in cancer.阿司匹林和抗血小板治疗在癌症中的应用。
Blood. 2021 Jun 10;137(23):3201-3211. doi: 10.1182/blood.2019003977.
5
Platelet-Mediated Protection of Cancer Cells From Immune Surveillance - Possible Implications for Cancer Immunotherapy.血小板介导的癌细胞免疫逃避及其对癌症免疫治疗的启示
Front Immunol. 2021 Mar 10;12:640578. doi: 10.3389/fimmu.2021.640578. eCollection 2021.
6
Regulation of PD-L1 expression in the tumor microenvironment.肿瘤微环境中 PD-L1 表达的调控。
J Hematol Oncol. 2021 Jan 7;14(1):10. doi: 10.1186/s13045-020-01027-5.
7
Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.NK 细胞的抗肿瘤作用和抗 PD-L1 抗体的抗体依赖性细胞细胞毒性在 PD-L1 阳性癌细胞系中的作用。
J Immunother Cancer. 2020 Aug;8(2). doi: 10.1136/jitc-2020-000873.
8
Transforming growth factor beta induces fibroblasts to express and release the immunomodulatory protein PD-L1 into extracellular vesicles.转化生长因子-β诱导成纤维细胞表达并将免疫调节蛋白 PD-L1 释放到细胞外囊泡中。
FASEB J. 2020 Feb;34(2):2213-2226. doi: 10.1096/fj.201902354R. Epub 2019 Dec 12.
9
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.程序性死亡配体 1(PD-L1)表达作为预测生物标志物的作用:对所有美国食品和药物管理局(FDA)批准的免疫检查点抑制剂的分析。
J Immunother Cancer. 2019 Oct 26;7(1):278. doi: 10.1186/s40425-019-0768-9.
10
Recent Findings in the Regulation of Programmed Death Ligand 1 Expression.程序性死亡配体 1 表达调控的最新研究发现。
Front Immunol. 2019 Jun 14;10:1337. doi: 10.3389/fimmu.2019.01337. eCollection 2019.